- Wu, Cheng-Chia;
- Wang, Tony JC;
- Jani, Ashish;
- Estrada, Juan P;
- Ung, Timothy;
- Chow, Daniel S;
- Soun, Jennifer E;
- Saad, Shumaila;
- Qureshi, Yasir H;
- Gartrell, Robyn;
- Saadatmand, Heva J;
- Saraf, Anurag;
- Garrett, Matthew D;
- Grubb, Christopher S;
- Isaacson, Steven R;
- Cheng, Simon K;
- Sisti, Michael B;
- Bruce, Jeffrey N;
- Sheth, Sameer A;
- Lassman, Andrew B;
- McKhann, Guy M
Background
Studies have shown racial differences in cancer outcomes. We investigate whether survival differences existed in Hispanic patients with glioblastoma (GBM) compared with other ethnicities from our modern radiotherapy series, because no study to date has focused on outcomes in this group after radiation therapy.Methods
We retrospectively evaluated 428 patients diagnosed with GBM from 1996 to 2014 at our institution, divided into 4 groups based on self-report: white, black, Hispanic, and Asian/Indian. The primary outcome was overall survival. We analyzed differences in prognostic factors among the whole cohort compared with the Hispanic cohort alone.Results
Baseline characteristics of the 4 racial groups were comparable. With a median follow-up of 387 days, no survival differences were seen by Kaplan-Meier analysis. Median overall survival for Hispanic patients was 355 days versus 450 days for the entire cohort. Factors significant for patient outcomes in the entire cohort differed slightly from those specific to Hispanic patients. Low Karnofsky Performance Status was significant on multivariate analysis in the whole population, but not in Hispanic patients. Extent of resection, recursive partitioning analysis class, and radiation therapy total dose were significant on multivariate analysis in both the whole population and Hispanic patients.Conclusions
We found that Hispanic patients with GBM had no difference in survival compared with other ethnicities in our cohort. Differences exist in factors associated with outcomes on single and multivariate analysis for Hispanic patients with GBM compared with the entire cohort. Additional studies focusing on Hispanic patients will aid in more personalized treatment approaches in this group.